Cargando…

Status of Current Biofluid Biomarkers in Parkinson's Disease

Detalles Bibliográficos
Autor principal:	Mollenhauer, Brit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2023
Materias:	Viewpoints
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448129/ https://www.ncbi.nlm.nih.gov/pubmed/37637982 http://dx.doi.org/10.1002/mdc3.13753

Ejemplares similares

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

Oral Biofluid Biomarker Research: Current Status and Emerging Frontiers
por: Wang, Austin, et al.
Publicado: (2016)

Temporal trajectory of biofluid markers in Parkinson’s disease
por: Baek, Min Seok, et al.
Publicado: (2021)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

Combining clinical and biofluid markers for early Parkinson's disease detection
por: Yu, Zhenwei, et al.
Publicado: (2017)

Elimination of schistosomiasis in China: Current status and future prospects
por: Wang, Wei, et al.
Publicado: (2021)

Tele-yoga for Chronic Pain: Current Status and Future Directions
por: Mathersul, Danielle C, et al.
Publicado: (2018)

Telepsychiatry Through Email Mode: Current Status and Consensus Guidelines
por: Innamuri, Raviteja, et al.
Publicado: (2020)

The current second wave and COVID-19 vaccination status in India
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives
por: Huang, Shan, et al.
Publicado: (2022)

Personalized medicine in Parkinson's disease: Time to be precise
por: Titova, Nataliya, et al.
Publicado: (2017)

Parkinson's disease: Is it a consequence of human brain evolution?
por: Diederich, Nico J., et al.
Publicado: (2019)

Current status of China's critical care medicine big data platform and future prospects
por: Su, Long-Xiang, et al.
Publicado: (2021)

Challenges in Parkinson’s Disease Care—In Light of the COVID-19 Pandemic
por: Woo, Kyung Ah, et al.
Publicado: (2023)

Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease
por: den Heijer, Jonas M., et al.
Publicado: (2020)

Remote Monitoring of Heart Failure in Patients with Implantable Cardioverter-Defibrillators: Current Status and Future Needs
por: Theuns, Dominic A. M. J., et al.
Publicado: (2021)

Mask on, Mask off: Subclinical Parkinson’s Disease Unveiled by COVID-19
por: Beckers, Milan, et al.
Publicado: (2023)

Toward Personalized Medicine Approaches for Parkinson Disease Using Digital Technologies
por: Khanna, Amit, et al.
Publicado: (2023)

Somatic Alpha-Synuclein Mutations in Parkinson's Disease: Hypothesis and Preliminary Data
por: Proukakis, Christos, et al.
Publicado: (2013)

Imaging the Functional Neuroanatomy of Parkinson’s Disease: Clinical Applications and Future Directions
por: Lauretani, Fulvio, et al.
Publicado: (2021)

Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?
por: Li, Dunhui, et al.
Publicado: (2022)

Management of Parkinson's Disease Dysarthria: Can Artificial Intelligence Provide the Solution?
por: Kumar, Raj, et al.
Publicado: (2022)

Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective
por: Vermeiren, Yannick, et al.
Publicado: (2020)

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
por: Leta, Valentina, et al.
Publicado: (2021)

Beyond the Dopaminergic System: Lessons Learned from levodopa Resistant Symptoms in Parkinson's Disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias
por: Carlyle, Becky C., et al.
Publicado: (2018)

Eccrine Sweat as a Biofluid for Profiling Immune Biomarkers
por: Katchman, Benjamin A., et al.
Publicado: (2018)

Biofluid lipidome: a source for potential diagnostic biomarkers
por: Ghosh, Arkasubhra, et al.
Publicado: (2017)

Polyamine Metabolites as Biomarkers in Head and Neck Cancer Biofluids
por: DeFelice, Brian C., et al.
Publicado: (2022)

Biomarkers in biological fluids for dementia with Lewy bodies
por: Schade, Sebastian, et al.
Publicado: (2014)

Does Restless Legs Syndrome Have a Different Pathomechanism in Premotor and Motor Parkinson’s Disease?
por: Calzetti, Stefano, et al.
Publicado: (2021)

Compensation Strategies for Gait Impairments in Parkinson's Disease: From Underlying Mechanisms to Daily Clinical Practice
por: Tosserams, Anouk, et al.
Publicado: (2022)

Medical Use, Decriminalization, and Legalization of Narcotic Drugs and Psychotropic Substances—What Does It Mean and What Is Its Current Status in India?
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2022)

Extracellular vesicles in the study of Alzheimer's and Parkinson's diseases: Methodologies applied from cells to biofluids
por: Vaz, Margarida, et al.
Publicado: (2022)

Con: Can biomarkers be gold standards in Alzheimer's disease?
por: Rockwood, Kenneth
Publicado: (2010)

Pro: Can biomarkers be gold standards in Alzheimer's disease?
por: Sperling, Reisa, et al.
Publicado: (2010)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

From Evidence to the Dish: A Viewpoint of Implementing a Thai-Style Mediterranean Diet for Parkinson’s Disease
por: Phokaewvarangkul, Onanong, et al.
Publicado: (2023)

Update on the Non-Huntington's Disease Choreas with Comments on the Current Nomenclature
por: Walker, Ruth H.
Publicado: (2012)

Targeting the Gut–Brain Axis with Fecal Microbiota Transplantation: Considerations on a Potential Novel Treatment for Parkinson's Disease
por: Contarino, Maria Fiorella, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_73ihiv8kscpuc97urhisp4au2s